Core-shell hybrid liposomal vesicles loaded with panax notoginsenoside: preparation, characterization and protective effects on global cerebral ischemia/reperfusion injury and acute myocardial ischemia in rats

Abstract

Purpose:Novel panax notoginsenoside-loaded core-shell hybrid liposomal vesicles (PNS-HLV) were developed to resolve the restricted bioavailability of PNS and to enhance its protective effects in vivo on oral administration.Methods:Physicochemical characterizations of PNS-HLV included assessment of morphology, particle size and zeta potential, encapsulation efficiency (EE%), stability and in vitro release study. In addition, to evaluate its oral treatment potential, we compared the effect of PNS-HLV on global cerebral ischemia/reperfusion and acute myocardial ischemia injury with those of PNS solution, conventional PNS-loaded nanoparticles, and liposomes.Results:In comparison with PNS solution, conventional PNS-loaded nanoparticles and liposomes, PNS-HLV was stable for at least 12 months at 4°C. Satisfactory improvements in the EE% of notoginsenoside R1, ginsenoside Rb1, and ginsenoside Rg1 were shown with the differences in EE% shortened and the greater controlled drug release profiles were exhibited from PNS-HLV. The improvements in the physicochemical properties of HLV contributed to the results that PNS-HLV was able to significantly inhibit the edema of brain and reduce the infarct volume, while it could markedly inhibit H2O2, modified Dixon agar, and serum lactate dehydrogenase, and increase superoxide dismutase (P < 0.05).Conclusion:The results of the present study imply that HLV has promising prospects for improving free drug bioactivity on oral administration.

Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson&rsquo;s disease models

“…173 Similarly, nanoliposomal vesicles loaded with panax notoginsenoside have a protective effect against cerebral ischemia and myocardial ischemia in rats. 174 …”

Therapeutic Potential of Natural Product-Based Oral Nanomedicines for Stroke Prevention

“…36 As a result, orally administered PNS-HLV exhibited greater effectiveness for attenuation of brain damage and bioactivities and achieved higher potency than the free drug, conventional nanoparticles, and liposomes in vivo.…”

“…Because liposomes can be unstable, leading to leakage of the entrapped drug after administration, modifications of the liposomal surface with a single layer of hydrophilic polymers or polyelectrolytes, or varying the size of liposomes have been tested in animal experiments. Zhang et al 36 recently introduced a novel liposomal system encapsulating methyl ether PEG-PLGA-based nanoparticles. These socalled core-shell hybrid liposomal vesicles (HLV), increase entrapment efficiency and retard destruction of drug components; the resulting vesicles showed suitable architecture and properties for oral application.…”

“…It is also reported that the amount of Rg1 (20.46%) absorbed via oral administration was within 1.9-20.0%. 43 Zhang et al 36 developed a novel PNS-loaded core-shell HLV (PNS-HLV; 337.8 -40.2 nm) to resolve the restricted bioavailability and retard the release of the major components of PNS to a similar degree to enhance its protective effects on global cerebral ischemia/reperfusion in a rat model in vivo. The formation of the HLV and its preparation method, the application of water-in-oil-in-water double emulsion solvent evaporation method and thin-film hydration method, are designed according to the polarities of the main components of PNS.…”

Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles

“…12,13,15 Recent advances in nanoscale drug carriers for MI therapy include liposomes (containing PEGylated liposomes), core-shell hybrid liposomal vesicles, lipid nanoparticles, etc. [16][17][18][19] In this study, we designed Sch B loaded PEG-modified solid lipid nanoparticles (SLNs) for MI treatment.…”